VNVincenzo Di Noia

Vincenzo Di Noia

*This is an algorithmically generated author record based on publicly available information.

Vincenzo Di Noia has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer

    by V. Di Noia, F. Pimpinelli, D. Renna, V. Barberi, R. Pellini, A. Morrone, D. Giannarelli, F. Cognetti


  • Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

    by Vincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, Vittoria Barberi, Maria Teresa Maccallini, Ludovica Gariazzo, Martina Pontone, Alessandro Monti, Flaminia Campo, Emanuela Taraborelli, et al.

    Purpose: We assessed the immunogenicity and safety of the BNT162b2 vaccine in a large cohort of patients with cancer (CP). Experimental Design: From March 1, 2021 to March 20, 2021, this prospective cohort study included 816 CP afferent to our institution and eligible for the vaccination. A cohort of 274 health care workers (HCW) was used as age- and sex-matched control group. BNT162b2 was administered as a two-dose regimen given 21 days apart. Blood samples to analyze anti-Spike (S) IgG antibodies (Ab) were collected prevaccination [timepoint (TP) 0], and at 3 weeks (TP1) and 7 weeks (TP2) after the first dose. Results: Patients characteristics: median age 62 (range, 21–97); breast/lung cancer/others (31/21/48%); active treatment/follow-up (90/10%). In the whole CP cohort, the serologic response rate (RR) and the titre of anti-S IgG significantly increased across the TPs; at TP2, the responders (IgG >15 AU/mL) were 94.2%. Active chemotherapy and chronic use of steroids were independent predictors of lower RR. Adverse events (AE) after the booster predicted higher likelihood of response (OR, 4.04; 95% confidence interval, 1.63–9.99; P = 0.003). Comparing the matched cohorts, the responders were significantly lower in CP than in HCW at TP1 (61.2% vs. 93.2%) and TP2 (93.3% vs. 100%), while the geometric mean concentration of IgG did not significantly differ at TP2 being significantly lower in CP (23.3) than in HCW (52.1) at TP1. BNT162b2 was well tolerated in CP; severe-grade AEs were 3.5% and 1.3% after the first and second doses, respectively. Conclusions: BNT162b2 assures serologic immunization without clinically significant toxicity in CP. The second dose is needed to reach a satisfactory humoral response.


  • Open Access

    Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

    by V. Di Noia, A. D’aVeni, E. D’aRgento, S. Rossi, P. Ghirardelli, L. Bortolotti, V. Vavassori, E. Bria, G.L. Ceresoli


  • Open Access

    Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers

    by Flaminia Campo, Aldo Venuti, Fulvia Pimpinelli, Elva Abril, Giovanni Blandino, Laura Conti, Armando De Virgilio, Federico De Marco, Vincenzo Di Noia, Enea Gino Di Domenico, et al.

    Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. Methods: An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by the national vaccine campaign at the beginning of 2021. Serum samples were collected on day 1 just prior to the first dose of the vaccine and on day 21 just prior to the second vaccination dose. Thereafter sera samples were collected 28, 49, 84 and 168 days after the first dose of BNT162b2. Quantitative measurement of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was performed with a commercial chemiluminescent immunoassay. Results: Two hundred seventy-four HWCs were analyzed, 175 women (63.9%) and 99 men (36.1%). The maximum antibody geometric mean concentration (AbGMC) was reached at T2 (299.89 AU/mL; 95% CI: 263.53–339.52) with a significant increase compared to baseline (p < 0.0001). Thereafter, a progressive decrease was observed. At T5, a median decrease of 59.6% in COVID-19 negative, and of 67.8% in COVID-19 positive individuals were identified with respect to the highest antibody response. At T1, age and previous COVID-19 were associated with differences in antibody response, while at T2 and T3 differences in immune response were associated with age, gender and previous COVID-19. At T4 and T5, only COVID-19 positive participants demonstrated a greater antibody response, whereas no other variables seemed to influence antibody levels. Conclusions: Overall our study clearly shows antibody persistence at 6 months, albeit with a certain decline. Thus, the use of this vaccine in addressing the COVID-19 pandemic is supported by our results that in turn open debate about the need for further boosts.


  • The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey

    by Vincenzo Di Noia, Davide Renna, Vittoria Barberi, Mattia Di Civita, Federica Riva, Giulia Costantini, Emanuela Dell’ Aquila, Michelangelo Russillo, Domenico Bracco, Antonia Marina La Malfa, et al.